Adverse events1,316

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,316

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhoea	Gastrointestinal disorders	Solanezumab: Double-Blind Phase	76	1,054	86
other	Diarrhoea	Gastrointestinal disorders	Placebo: Double-Blind Phase	87	1,067	109
other	Diarrhoea	Gastrointestinal disorders	Solanezumab: Open Label	23	879	24
other	Diarrhoea	Gastrointestinal disorders	Placebo: Open Label	17	856	18
other	Nausea	Gastrointestinal disorders	Solanezumab: Double-Blind Phase	54	1,054	69
other	Nausea	Gastrointestinal disorders	Placebo: Double-Blind Phase	46	1,067	63
other	Nausea	Gastrointestinal disorders	Solanezumab: Open Label	23	879	32
other	Nausea	Gastrointestinal disorders	Placebo: Open Label	15	856	18
other	Nasopharyngitis	Infections and infestations	Solanezumab: Double-Blind Phase	89	1,054	114
other	Nasopharyngitis	Infections and infestations	Placebo: Double-Blind Phase	80	1,067	99
other	Nasopharyngitis	Infections and infestations	Solanezumab: Open Label	29	879	31
other	Nasopharyngitis	Infections and infestations	Placebo: Open Label	32	856	36
other	Upper respiratory tract infection	Infections and infestations	Solanezumab: Double-Blind Phase	64	1,054	74
other	Upper respiratory tract infection	Infections and infestations	Placebo: Double-Blind Phase	54	1,067	61
other	Upper respiratory tract infection	Infections and infestations	Solanezumab: Open Label	23	879	25
other	Upper respiratory tract infection	Infections and infestations	Placebo: Open Label	21	856	23
other	Urinary tract infection	Infections and infestations	Solanezumab: Double-Blind Phase	58	1,054	79
other	Urinary tract infection	Infections and infestations	Placebo: Double-Blind Phase	72	1,067	103
other	Urinary tract infection	Infections and infestations	Solanezumab: Open Label	38	879	47
other	Urinary tract infection	Infections and infestations	Placebo: Open Label	36	856	46

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01900665/events

API reference For AI assistants

Adverse events1,316

Sources 3

Read this list from software.